| 18.84 2.1 (12.54%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.01 |
1-year : | 25.71 |
| Resists | First : | 18.85 |
Second : | 22.01 |
| Pivot price | 15.8 |
|||
| Supports | First : | 16.18 |
Second : | 14.53 |
| MAs | MA(5) : | 16.93 |
MA(20) : | 15.6 |
| MA(100) : | 14.59 |
MA(250) : | 12.06 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 95.7 |
D(3) : | 91.4 |
| RSI | RSI(14): 84.8 |
|||
| 52-week | High : | 18.85 | Low : | 0.54 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMRN ] has closed It is unclear right now based on current values. 77.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.86 - 18.92 | 18.92 - 18.98 |
| Low: | 16.61 - 16.67 | 16.67 - 16.74 |
| Close: | 18.72 - 18.82 | 18.82 - 18.94 |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Mon, 29 Sep 2025
Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom (NASDAQ:AMRN) - Seeking Alpha
Sat, 30 Aug 2025
44% Cardiovascular Risk Reduction: Amarin's VASCEPA Proves Powerful in Multiple High-Risk Patient Groups at ESC - Stock Titan
Thu, 14 Aug 2025
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Wed, 30 Jul 2025
Amarin Corporation Q2 2025 Financial Results - TradingView
Tue, 29 Jul 2025
What To Expect From Amarin Corp PLC (AMRN) Q2 2025 Earnings - Yahoo Finance
Wed, 25 Jun 2025
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 374 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 425 (K) |
| Shares Short P.Month | 477 (K) |
| EPS | -5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.37 |
| Profit Margin | -47.3 % |
| Operating Margin | 9.3 % |
| Return on Assets (ttm) | -4.4 % |
| Return on Equity (ttm) | -20.4 % |
| Qtrly Rev. Growth | 7.8 % |
| Gross Profit (p.s.) | 5.73 |
| Sales Per Share | 10.6 |
| EBITDA (p.s.) | -2.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | -3.77 |
| PEG Ratio | 0 |
| Price to Book value | 0.84 |
| Price to Sales | 1.77 |
| Price to Cash Flow | -33.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|